{
  "url": "https://struct.news/briefs/erascas-clinical-spending-rose-as-cash-fell-and-its-share-count-climbed",
  "title": "Erasca's clinical spending rose as cash fell and its share count climbed",
  "summary": "The biotech ended June with $42.5 million in cash after using $54.7 million in operations during six months.",
  "published_at": "2026-08-11T23:46:35.652316+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Erasca, Inc.",
    "ticker": "ERAS",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-11",
    "accession": "0001193125-26-344611",
    "url": "https://www.sec.gov/Archives/edgar/data/1761918/000119312526344611/eras-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-12",
    "url": "https://www.sec.gov/Archives/edgar/data/1761918/000119312525178996/eras-20250630.htm"
  },
  "reported_figures": [],
  "watch_next": [
    {
      "type": "partner_dependency",
      "statement": "Existence and terms of the March 2026 clinical trial collaboration and supply agreement with Tango to evaluate ERAS-0015 with vopimetostat in a Phase 1 trial.",
      "importance": "medium",
      "evidence": "In March 2026, we announced that we had entered into a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. (Tango) to enable the evaluation of ERAS-0015 with Tango's PRMT5 inhibitor, vopimetostat, in a Phase 1 clinical trial sponsored by Tango (the Tango CTCSA).",
      "source_date": "2026-05-11"
    }
  ],
  "related_tickers": [
    "ERAS"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}